Skip to main content

  • ASSAIL-MI Trial: IL-6 Inhibition with Tocilizumab Increased Myocardial Salvage by 5.6% vs. Placebo in STEMI Patients

    • Posted: 04/12/2021
    • Author:

      Natalie Morrison, CRTonline.org

    The interleukin-6 (IL-6) inhibitor tocilizumab increased myocardial salvage by 5.6% versus placebo in ST-segment elevation myocardial infarction (STEMI) patients in the Norwegian ASSAIL-MI trial.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details